Radiation oncology firm Accuray is highlighting clinical studies featuring its TomoTherapy system that were presented at the American Association of Physicists in Medicine (AAPM) meeting in Anaheim, CA.
Researchers at the University of Arkansas for Medical Sciences and the University of Texas Southwestern Medical Center presented results of TomoHelical-based spatially fractionated radiotherapy for deep-seated tumors. They found that the protocol was better able to spare some critical structures, according to Accuray.
Also, researchers at Samsung Medical Center in Seoul, South Korea, found that Accuray's TomoHelical and TomoDirect intensity-modulated radiation therapy (IMRT) plans provided better target coverage than conventional plans in lung cancer patients.
Finally, a study conducted at the University of California, Los Angeles (UCLA) assessed the correlation between improved clinical outcomes and required treatment dose for adjuvant mesothelioma radiotherapy with either the TomoTherapy system or conventional 3D techniques. The researchers found that the TomoTherapy system provided better target coverage and less heterogeneity, even for large and irregular treatment sites, the company said.
